An observational study in Breast Cancer, Chemotherapy and Biodex Gait Trainer, sponsored by Adly A Adam. Recruiting at 1 site in Egypt. Open to female participants aged 40 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Adly A Adam · Observational
Breast cancer is considered the most common type of malignancies, it is the most frequently diagnosed representing around 2.3 million cases. Where, their chemotherapy may cause fatigue affecting the overall quality of patient's life. Gait and balance are fundamental for activities of daily living and maintaining functional independence.
Gait disturbance is one of the side effects that occur after chemotherapy due to various reasons resulting in lower values of quality of life. Chemotherapeutic agents can cause muscle wasting particularly in the lower extremities resulting in reduced strength and balance. Gait dysfunction, and falls may have particularly severe consequences in this population due to comorbidities increasing the risk of fall-related injury. Therefore, this study was designed to assess gait parameters in breast cancer patient receiving chemotherapy to assist in designing on optimal rehabilitation program based on objective data derived from our study for gait dysfunction in breast cancer patients receiving chemotherapy.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 360 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Adly A Adam is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
360 female patients aged from 40 to 50 years, suffering from breast cancer and receiving chemotherapy will be randomly selected from National Cancer Institute, Cairo, Egypt
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
360 female patients aged from 40 to 50 years, suffering from breast cancer and receiving chemotherapy
Other: Gait parameter assessment
A Biodex Gait Trainer 3 (BIODEX MEDICAL SYSTEMS, INC., New York, NY, model NO. 601-1-M90, EN 60601- 1 USA), is a device which is used to assess the spatiotemporal gait parameters of patients . It consists of a treadmill with an instrumented deck that monitors and records kinematic gait parameters including gait speed, step cycle, step length, and time on each foot (step symmetry). The patient will instructed to stand on the treadmill holding on handrails to ensure safety. Each patient will be asked to walk continuously for 3 minutes, till the evaluation session ended, and the gait trainer slow down gradually until it stopped. Three successive trials will be done for each patient. The mean value of each variable of spatiotemporal parameters of gait \[walking speed (meters per seconds), step cycle (cycle per second), step length (meter), and time on each foot (seconds)\] will be recorded.
Walking Speed (Meter per second)
Walking Speed in unit of measurement is meter per second.
Time frame: One time assessment throughout the study completion an average of 3 months.
Step cycle (cycle per second)
Step cycle: in unit of measurement is Cycle per second.
Time frame: One time assessment throughout the study completion an average of 3 months.
Step length (Meter)
Step length in unit of measurement is meter.
Time frame: One time assessment throughout the study completion an average of 3 months.
Time on each foot (Seconds)
Time on each foot in unit of measurement is seconds
Time frame: One time assessment throughout the study completion an average of 3 months.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adly A Adam